NCT02330510View on ClinicalTrials.gov

Amyloid and Glucose PET Imaging in Alzheimer and Vascular Cognitive Impairment Patients With Significant White Matter Disease

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

December 10, 2024

Study Completion Date

December 10, 2024

Conditions

Alzheimer's DiseaseSmall Vessel Disease White Matter Hyperintensities SubtypeVascular Cognitive Impairment

Trial Locations (8)

Unknown

University of Alberta Health Services, Calgary

CHU de Quebec, Québec

V6T 2B5

University of British Columbia Hospital, Vancouver

L8L 2X2

Hamilton General Hospital, Hamilton

N6C 5J1

Parkwood Hospital St. Joseph's Health Care, London

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

H3T 1E2

Jewish General Hospital, Montreal

J1H 5H3

CHU de Sherbrooke, Québec

All Listed Sponsors

lead

Dr. Sandra E Black

OTHER

NCT02330510 - Amyloid and Glucose PET Imaging in Alzheimer and Vascular Cognitive Impairment Patients With Significant White Matter Disease | Biotech Hunter | Biotech Hunter